10-K: BioMarin Reports $3.2B Revenue, Strategic Acquisitions, and ROCTAVIAN Withdrawal in 2025

BioMarin Pharmaceutical Inc. achieved $3.2 billion in total revenues in 2025, driven by VOXZOGO expansion, while strategically withdrawing ROCTAVIAN from the market and pursuing significant acquisitions to bolster its rare disease portfolio.

Summary

• Total revenues for 2025 reached $3.2 billion, an increase from $2.85 billion in 2024, primarily driven by the expansion of VOXZOGO.
• Net income for 2025 was $348.9 million, a decrease from $426.9 million in 2024.
• The company entered into a definitive agreement in December 2025 to acquire Amicus Therapeutics, Inc. for approximately $4.8 billion in an all-cash transaction, expected to close in Q2 2026.
• The Amicus acquisition will add two new therapies for Fabry disease and late-onset Pompe disease to BioMarin's commercial portfolio.
• Financing for the Amicus acquisition includes cash on hand and approximately $3.7 billion of non-convertible debt financing, with $850.0 million in 5.5% senior unsecured notes due 2034 issued in February 2026.
• BioMarin committed to voluntarily withdrawing ROCTAVIAN from the market in December 2025 due to lower than anticipated commercial opportunities, resulting in $240.0 million in restructuring charges in 2025.
• The restructuring charges for ROCTAVIAN included a $119.2 million inventory write-off, $118.5 million impairment of long-lived assets, and $3.5 million in severance and other costs.
• The acquisition of Inozyme Pharma, Inc. was completed in July 2025 for approximately $285.0 million, adding BMN 401 for ENPP1 deficiency to the enzyme therapies portfolio.
• Research and Development (R&D) expenses increased to $921.9 million in 2025, primarily due to a $221.0 million In-Process Research and Development (IPR&D) charge from the Inozyme acquisition and continued progression of VOXZOGO for hypochondroplasia.
• Selling, General and Administrative (SG&A) expenses increased to $1,153.0 million in 2025, partly due to ROCTAVIAN asset impairment and global expansion of VOXZOGO.
• VOXZOGO net product revenues grew to $926.9 million in 2025 from $735.1 million in 2024, driven by new patient initiations across all regions.
• KUVAN product revenues decreased to $99.6 million in 2025 from $120.9 million in 2024 due to increasing generic competition.
• The company's cash, cash equivalents, and investments totaled $2.05 billion as of December 31, 2025.
• Net cash provided by operating activities increased to $828.0 million in 2025 from $572.8 million in 2024.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive outlook, balancing strong revenue growth and strategic acquisitions with the significant financial impact of the ROCTAVIAN withdrawal and increased debt for M&A.

Positives

• Total revenues increased to $3.2 billion in 2025, demonstrating continued commercial growth.
• VOXZOGO sales showed strong growth, reaching $926.9 million in 2025, driven by new patient initiations globally.
• The acquisition of Amicus Therapeutics is expected to strengthen and diversify the commercial portfolio with two new rare disease therapies.
• The acquisition of Inozyme Pharma added BMN 401, a late-stage enzyme replacement therapy for ENPP1 deficiency, to the pipeline.
• Progress in the pipeline includes advancing the CANOPY clinical program for VOXZOGO in multiple growth disorders and positive Phase 1/2 data for BMN 351 in Duchenne Muscular Dystrophy.
• Net cash provided by operating activities significantly increased to $828.0 million in 2025.
• VOXZOGO has U.S. orphan drug exclusivity until 2030 and EU orphan drug exclusivity until 2031, providing a competitive advantage.
• Key patents for VOXZOGO and PALYNZIQ have received term extensions in the U.S. and EU, enhancing intellectual property protection.

Negatives

• Net income decreased to $348.9 million in 2025 from $426.9 million in 2024.
• The voluntary withdrawal of ROCTAVIAN from the market resulted in $240.0 million in restructuring charges in 2025.
• Gross margin decreased to 77.7% in 2025 from 79.7% in 2024, primarily due to the ROCTAVIAN inventory write-off.
• KUVAN revenues continue to decline due to increasing generic competition.
• Increased R&D expenses in 2025 were partly due to a $221.0 million IPR&D charge from the Inozyme acquisition.
• Increased SG&A expenses in 2025 were partly due to restructuring charges related to ROCTAVIAN asset impairment.
• The company expects interest expense to increase over the next 12 months due to financing related to the Amicus acquisition.

Risks

• The pending Amicus Acquisition may not be completed on the currently contemplated timeline or terms, or at all, due to regulatory clearances, stockholder approval, or other closing conditions.
• Anticipated benefits from the Amicus Acquisition, such as operational synergies and cost savings, may not be fully realized or may take longer and cost more than expected.
• The integration of acquired businesses like Amicus and Inozyme could divert management's attention, lead to loss of key employees, disrupt ongoing operations, or result in unforeseen liabilities.
• Failure to obtain and maintain adequate coverage and reimbursement for products by third-party payers could adversely affect sales and profitability, especially given the high per-patient prices for rare disease treatments.
• Generic competition, particularly for KUVAN, continues to negatively impact revenues and could materially affect sales of other products in the future.
• Changes in methods of disease treatment, such as the widespread adoption of gene therapy, could reduce demand for existing enzyme replacement therapies.
• Regulatory approval for product candidates is lengthy, expensive, and uncertain, with no guarantee of success or timely approval in all desired markets.
• Products are subject to extensive ongoing regulatory requirements, and failure to comply or unanticipated problems could lead to penalties, reduced revenues, or withdrawal of marketing approval.
• Preliminary or interim clinical trial data may not be predictive of final results, and product candidates may fail in later stages despite promising early data.
• Government price controls, healthcare reform initiatives (like the IRA and potential MFN pricing), and cost-containment measures could restrict pricing and reimbursement, adversely affecting revenues and results of operations.
• Failure to obtain the necessary capital to fund operations could lead to delays or termination of product development programs.
• Substantial indebtedness incurred for acquisitions may decrease business flexibility, access to capital, and increase borrowing costs.
• Failure to comply with manufacturing regulations or inability to produce sufficient quantities of products at acceptable costs could disrupt supply, delay approvals, or reduce revenues.
• Dependence on single-source suppliers for critical raw materials and limited manufacturing facilities poses risks of supply interruptions.
• International operations expose the company to risks such as diverse regulatory requirements, geopolitical instability, diminished intellectual property protection, tariffs, currency fluctuations, and anti-corruption compliance.
• Reliance on special access programs for international sales carries risks of changes in requirements, funding levels, or unofficial measures to limit purchases.
• Inability to protect intellectual property through patents, trade secrets, or against infringement claims could limit market competitiveness.
• The company is subject to a U.S. Department of Justice subpoena regarding sponsored testing programs for VIMIZIM and NAGLAZYME, with an uncertain outcome.
• Cybersecurity threats and incidents could harm business operations, lead to data loss, reputational damage, and significant costs.
• Activist investor actions could cause substantial costs, divert management attention, and create uncertainty about strategic direction.

Future Outlook

BioMarin expects to continue growing its commercial business and advancing its product candidate pipeline through internal research, partnerships, and acquisitions. The Amicus Therapeutics acquisition is anticipated to close in the second quarter of 2026, strengthening the commercial portfolio. The company plans to finance this transaction through cash on hand and new debt facilities, which will increase interest expense. BioMarin will continue to monitor macroeconomic conditions and adjust business processes to mitigate risks. The company believes current cash and future cash flows from operations, along with external financings, will be sufficient to meet liquidity requirements for at least the next 12 months and longer-term obligations.

Management Comments

• Alexander Hardy, President & Chief Executive Officer, certified that the Annual Report on Form 10-K does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made not misleading, and that the financial statements fairly present the financial condition, results of operations, and cash flows.
• Brian R. Mueller, Executive Vice President, Finance & Chief Financial Officer, certified the same regarding the Annual Report on Form 10-K.
• Management believes that the combination of internal research programs, partnerships, and acquisitions of external assets will allow the company to continue to develop and commercialize innovative therapies for patients with serious and life-threatening rare diseases and medical conditions.
• Management expects interest income to decrease over the next 12 months due to lower cash and investment balances as the pending Amicus acquisition will be financed through a combination of cash on hand and non-convertible debt financing.
• Management expects interest expense to increase over the next 12 months due to financing related to the pending Amicus acquisition, including the 2034 Notes issued on February 12, 2026.

Industry Context

StockSavvy.ai notes that BioMarin's strategic moves reflect broader trends in the biotechnology sector, particularly the focus on rare diseases and the increasing importance of M&A for pipeline expansion and market diversification. The withdrawal of ROCTAVIAN highlights the inherent risks and commercial challenges in gene therapy, even after regulatory approval, underscoring the need for robust market opportunity assessment. The company's continued investment in its VOXZOGO franchise and other enzyme therapies positions it within a growing segment of the rare disease market, while facing competition from both established players and emerging technologies like gene therapy. The significant debt financing for the Amicus acquisition indicates a strategic commitment to growth through external innovation, a common strategy among larger biopharmaceutical firms seeking to replenish pipelines and expand market reach.

Comparison to Industry Standards

• BioMarin's 2025 revenue growth of 12.8% ($3.22B from $2.85B) is robust, especially considering the strategic withdrawal of ROCTAVIAN. This growth is primarily driven by VOXZOGO, which is a key differentiator in the achondroplasia market, where competitors like Ascendis Pharma A/S and QED Therapeutics, Inc. are developing clinical-stage products.
• The voluntary withdrawal of ROCTAVIAN, a gene therapy for severe hemophilia A, due to lower than anticipated commercial opportunities, contrasts with the initial high expectations for gene therapies in the industry. This decision reflects a pragmatic approach to portfolio management, similar to other large pharma companies that periodically prune less commercially viable assets, though the scale of the write-off ($240M) is notable.
• The acquisition of Amicus Therapeutics for $4.8 billion, adding therapies for Fabry disease and late-onset Pompe disease, aligns with industry trends of consolidating rare disease portfolios. This strategy is comparable to moves by companies like Sanofi (BioMarin's partner for ALDURAZYME) and Takeda, which have also made significant investments in rare disease assets to diversify and strengthen their market positions.
• The company's R&D spending, including a $221.0 million IPR&D charge for the Inozyme acquisition, demonstrates a continued commitment to pipeline development, which is standard for a biotechnology company. The focus on enzyme replacement therapies and longer-acting CNP analogs positions BioMarin against a diverse set of competitors in specific rare disease indications, such as PTC Therapeutics in PKU and various gene therapy developers in MPS diseases.
• The gross margin of 77.7% in 2025, despite the ROCTAVIAN write-off, remains strong and is generally competitive within the specialized rare disease pharmaceutical sector, which typically commands higher margins due to high unmet medical need and premium pricing.

Corporate Governance

Legal Proceedings

• Received a subpoena from the U.S. Department of Justice requesting documents regarding sponsored testing programs relating to VIMIZIM and NAGLAZYME. The company is cooperating fully, but the outcome of the investigation is uncertain.

Related Party Transactions

• BioMarin/Genzyme LLC, a 50/50 limited liability company with Sanofi, holds intellectual property for ALDURAZYME and other collaboration products. BioMarin manufactures ALDURAZYME and supplies it to Sanofi, receiving payments ranging from 39.5% to 50% on worldwide net sales by Sanofi.

Stakeholder Impact

• **Shareholders**: Potential dilution from convertible debt conversion, volatility in stock price due to strategic decisions (ROCTAVIAN withdrawal, Amicus acquisition), and macroeconomic conditions. The Amicus acquisition is a significant investment that could drive future growth but also introduces integration risks and increased debt.
• **Patients**: Continued access to existing rare disease therapies and potential for new treatments from the expanded pipeline (VOXZOGO, BMN 333, BMN 351, BMN 401) and acquired Amicus therapies. Withdrawal of ROCTAVIAN means patients with severe hemophilia A will need alternative treatments.
• **Employees**: Workforce reductions associated with the ROCTAVIAN withdrawal, but also potential growth and new opportunities from acquisitions (Amicus, Inozyme) and pipeline expansion. Focus on competitive compensation, well-being, and professional growth to attract and retain talent.
• **Customers/Distributors**: Impacted by product availability (ROCTAVIAN withdrawal), pricing and reimbursement changes, and potential supply chain disruptions. Increased product portfolio with Amicus acquisition.
• **Creditors**: Increased debt burden due to financing for the Amicus acquisition, potentially affecting credit risk and borrowing costs. Existing convertible notes mature in 2027 and 2034.

Next Steps

• Close the acquisition of Amicus Therapeutics, Inc. in the second quarter of 2026.
• Enter into a senior secured term loan facility for approximately $2.8 billion and a new $600.0 million senior secured revolving credit facility in 2026.
• Continue to advance the CANOPY clinical program for VOXZOGO for the treatment of hypochondroplasia, idiopathic short stature, Noonan syndrome, Turner syndrome, and SHOX deficiency.
• Continue development of BMN 333 for multiple growth disorders.
• Progress BMN 351 for the treatment of Duchenne Muscular Dystrophy.
• Monitor and manage macroeconomic risks, including inflation, interest rates, and foreign currency exchange rates.
• Continue to evaluate additional guidance released by the OECD regarding Pillar Two rules and pending legislative adoption by individual countries.

Key Dates

Recommendation

BioMarin's 2025 performance shows strong revenue growth driven by its core products, particularly VOXZOGO, and a clear strategic direction through significant acquisitions like Amicus Therapeutics to expand its rare disease portfolio. However, the substantial restructuring charges and the withdrawal of ROCTAVIAN, coupled with increased debt for M&A, introduce near-term financial headwinds and integration risks. While the long-term potential from an expanded pipeline and market presence is attractive, the immediate impact on net income and gross margin, along with ongoing generic competition for KUVAN and regulatory uncertainties, suggests a 'hold' recommendation. Investors should monitor the successful integration of Amicus, the performance of new therapies, and the management of the increased debt load before considering a more aggressive stance.

Keywords

Rare Disease, Biotechnology, Pharmaceutical, VOXZOGO, Achondroplasia, Amicus Therapeutics, Acquisition, ROCTAVIAN, Gene Therapy, Enzyme Replacement Therapy, SEC Filing, 10-K, Financial Results, Pipeline, Clinical Trials, Orphan Drug, Intellectual Property, Debt Financing, Corporate Strategy, Risk Management